MedWorm provides a medical RSS filtering service. Over 6000 RSS medical sources are combined and output via different filters. This feed contains the latest medical blog items that have been tagged with 'effient'. Sat, 03 Sep 2011 02:53:47 +0100 http://www.medworm.com/index.php?rid=4027354&cid=t_188012_150_f&fid=34768&url=http%3A%2F%2Fpharmagossip.blogspot.com%2F2010%2F10%2Flilly-set-nearly-100-price-premium-for.html Source (Source: PharmaGossip) PharmaGossip blogs http://www.medworm.com/rss/comments.php?id=4027354 Sun, 03 Oct 2010 11:40:00 +0100 4027354 http://www.medworm.com/index.php?rid=3718698&cid=t_188012_150_f&fid=35777&url=http%3A%2F%2Ffeedproxy.google.com%2F%7Er%2FPharmalot%2F%7E3%2Fh68KkPeH3gU%2F Rise and shine, everyone. Another day is on the way. This means, of course, that meetings and deadlines beckon. Never mind that a holiday weekend is just around the corner. To cope, we are brewing the mandatory cup of stimulation, and enjoying an unexpectedly cool breeze. So please join us as we peruse the news of the world. Good luck today and catch you soon… AstraZeneca Loses Bid To Overturn Antitrust Fine (Dow Jones) Biogen Names Exelisis’ George Scangos As CEO (Bloomberg News) Recession Hurts Funding For AIDS Drug Program (New York Times) FDA Issues Latest List Of Drug With Possible Risks (Reuters) Quebec To Cut Generic Drug Prices (PharmaTimes) USPTO Denies Request To Re-Examine Plavix Patent (Dow Jones) Michigan Grows CROs (Xconomy) Calistoga Raises $40M To Fund Drug Tria... Pharmalot blogs http://www.medworm.com/rss/comments.php?id=3718698 Thu, 01 Jul 2010 11:56:22 +0100 3718698 http://www.medworm.com/index.php?rid=3710796&cid=t_188012_150_f&fid=35777&url=http%3A%2F%2Ffeedproxy.google.com%2F%7Er%2FPharmalot%2F%7E3%2FadDs09EjmRs%2F For Eli Lilly execs, the bleeding may never stop. The latest concern over its Effient blood thinner, which the drugmaker still hopes will stanch some revenue that will be lost due to patent expirations on big sellers, is the risk of cancer. The medication was linked to higher cancer rates than Plavix, the league-leading blood thinner, in an analysts of previously unpublished data. Effient yielded a 43 percent higher rate of solid tumors, excluding some skin cancers and brain tumors, than patients on Plavix. And the rate of solid tumors, other than brain and some skin cancers, was 1.4 percent in Effient patients but only 0.9 percent of Plavix patients. The analysis in the Archives of Internal Medicine examined data from the Triton-Timi 38 that Lilly submitted to the FDA for approval to sell... Pharmalot blogs http://www.medworm.com/rss/comments.php?id=3710796 Tue, 29 Jun 2010 13:02:06 +0100 3710796 http://www.medworm.com/index.php?rid=3560498&cid=t_188012_150_f&fid=35777&url=http%3A%2F%2Ffeedproxy.google.com%2F%7Er%2FPharmalot%2F%7E3%2F6PUQzXUi6TE%2F Pontificators are having a field day deciphering healthcare reform and PricewaterhouseCoopers is no exception. The consulting firm has just released a report concluding that, despite expanded coverage that will increase revenue, overall drug sales will decline by 4.3 percent from what they would have been otherwise between 2010 and 2019. The bill increases Medicaid rebates, expands discounts to 340b hospitals, requires Medicare Part D discounts and adds a big fees over 10 years. Specifially, a typical big pharma should see a 4 percent drop in revenue, and a large generic drugmaker should see a 2 percent boost. Meanwhile, a medium-size drugmaker with low government sales should expect only a 1 percent decline, but a large drugmaker with lots of government sales can expect a 7 percent drop. ... Pharmalot blogs http://www.medworm.com/rss/comments.php?id=3560498 Thu, 13 May 2010 11:16:46 +0100 3560498 http://www.medworm.com/index.php?rid=3499253&cid=t_188012_131_f&fid=35743&url=http%3A%2F%2Fthegenesherpa.blogspot.com%2F2010%2F04%2F99-usd-dna-day-and-patient-letters.html Yes,What a great DNA Day! Today started with my twitter feed notifying me that 23andMe had dropped their prices to 99 USD today. Which almost had me encouraging people to get testing, until I remembered that 23andSerge would then have your DNA..........FOREVER! Then I opened my email and read this great note"Dear Dr. Murphy,Thank you so very much. I am so lucky to have found your team. Who would have thought my Plavix might not be working for me? Only when you told me about how it could not work did I realize that I might be taking something that is worthless. Thanks for testing me. Now that I am on Effient I feel much safer!Thank you Dr. Murphy,You saved my life!"That's right. A genetic test, may have saved this patient from a heart attack. A genetic test I do regularly. Who has this pati... Gene Sherpas: Personalized Medicine and You blogs http://www.medworm.com/rss/comments.php?id=3499253 Fri, 23 Apr 2010 15:29:00 +0100 3499253 http://www.medworm.com/index.php?rid=3269872&cid=t_188012_150_f&fid=34768&url=http%3A%2F%2Fpharmagossip.blogspot.com%2F2010%2F02%2Feven-if-company-isnt-ready-to-give-up.html Eli Lilly had billion-dollar hopes when the blood thinner Effient was approved by the Food and Drug Administration last summer.But Lilly’s latest financial report shows the product — its first new drug in four years — is having trouble catching on.After sales of $22 million in its first quarter on the market, sales in the subsequent quarter fell to $3.8 million, hardly portending a blockbuster, and analysts slashed their projections.The faltering start of a new drug in a $6 billion market may also hold broader lessons for the nation’s pharmaceutical industry. Some analysts say it shows that the big drug companies need to grow more from mergers and acquisitions than from research and development.The disappointment raises pressure on Lilly, one of the world’s top 12 drug makers, to... PharmaGossip blogs http://www.medworm.com/rss/comments.php?id=3269872 Sat, 13 Feb 2010 02:05:00 +0100 3269872 http://www.medworm.com/index.php?rid=3111616&cid=t_188012_131_f&fid=35743&url=http%3A%2F%2Fthegenesherpa.blogspot.com%2F2009%2F10%2Fok-fine-back-to-plavix_4857.html Did anyone else see this?Scripps and Eric Topol are going to be doing testing for 2C19 polymorphisms in their interventional dept."Scripps physicians will initially offer the genetic tests to elective stent patients before they undergo their procedures at Scripps Green Hospital. Eventually, Scripps may extend the offering to its other facilities across San Diego County."I have been prodding Greenwich Hospital to do this.....I hope they do......They could be the El Camino of the East. What are these guys, Topol et.al going to be doing? "Scripps patients carrying the gene risk variants will be considered for three treatment choices following their stent procedures, each on an individualized basis. Patients will either: Be given a routine 75 milligram dose of Plavix with careful surveillance;... Gene Sherpas: Personalized Medicine and You blogs http://www.medworm.com/rss/comments.php?id=3111616 Fri, 09 Oct 2009 11:25:00 +0100 3111616 http://www.medworm.com/index.php?rid=2183097&cid=t_188012_131_f&fid=35743&url=http%3A%2F%2Fthegenesherpa.blogspot.com%2F2009%2F02%2Fprasugrel-saves-clopidogrel.html You gotta love it. The other day I was talking to a pharma rep, yes I do speak with them.....and they were all excited about Effient (generic name Prasugrel). What are these medications and why was the Pharma Rep excited?Well, you see Plavix(generic name Clopidogrel) which is one of the top 3 selling medications in the world is given to people who have had a stroke or heart attack. This medication is given to prevent another heart attack or stroke......Also, this medication is given to people who have received stents in their coronary arteries. This is to prevent the stents from clogging up with platelets.......sort of a Drano in a pill so to speak.It is also given to people who are having an acute heart attack.These 2 medications are blood thinners. How do these thinners work? They block ... Gene Sherpas: Personalized Medicine and You blogs http://www.medworm.com/rss/comments.php?id=2183097 Thu, 12 Feb 2009 12:10:00 +0100 2183097 http://www.medworm.com/index.php?rid=1526156&cid=t_188012_150_f&fid=34768&url=http%3A%2F%2Fpharmagossip.blogspot.com%2F2008%2F06%2Flilly-effient-will-prasugrel-make-it.html On balance, yes. But the big question will be: if its a bit more effective but causes more side effects where will it be positioned? It could depend on the price. (Source: PharmaGossip) PharmaGossip blogs http://www.medworm.com/rss/comments.php?id=1526156 Tue, 17 Jun 2008 13:49:00 +0100 1526156